全球年销超80亿美元、“自免神药”乌帕替尼国内首仿获批,超40家药企抢滩

红星资本局
Apr 28

红星资本局4月28日消息,知名自身免疫病药物乌帕替尼缓释片迎来了国内首仿。4月27日,国家药监局官网显示,江苏华阳制药有限公司(简称“江苏华阳”)申报的4类仿制药乌帕替尼缓释片已于4月21日得到批准。  4月27日,江苏华阳也在其微信公众号发布了相关药品注册证书。红星资本局注意到,该公司在申报时选择了承诺在专利期内暂不上市的“3类专利声明”,而原研药专利将于2030年到期。4月28日,红星资本局...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10